Recent advances in the understanding of celiac disease

Therapeutic implications for the management of pediatric patients

John H. Kwon, Richard J. Farrell

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Celiac disease (CD) is an autoimmune condition occurring in genetically susceptible individuals characterized by inflammatory injury to the mucosa of the small intestine after the ingestion of wheat glutens or related barley and rye products. Originally thought to be highly prevalent only in Northern European populations, growing evidence indicates a much higher prevalence in many other regions, including the US as well as South America, North Africa, and Asia. The growing awareness that pediatric patients may present with quite diverse and protean manifestations and the significant impact of CD on childhood development has prompted efforts to increase CD awareness for the early diagnosis and treatment of this disease. The current diagnostic criteria for CD requires characteristic histologic findings in small bowel biopsies and clinical remission when placed on a gluten-free diet. Serologic testing for CD can provide additional support for the diagnosis of CD or a means to assess efficacy and adherence to a gluten-free diet. The mainstay of treatment remains the institution of a gluten-free diet. However, patients with refractory CD may require treatment with immunosuppressant medications. With the increased identification of specific gluten epitopes and understanding of the pathogenesis of CD, future therapies may rely on genetically altering gluten proteins, immunization techniques, or therapies focused on either the development of specific immune tolerance or regulation of mucosal inflammation.

Original languageEnglish (US)
Pages (from-to)375-388
Number of pages14
JournalPediatric Drugs
Volume8
Issue number6
DOIs
StatePublished - Dec 19 2006

Fingerprint

Celiac Disease
Pediatrics
Gluten-Free Diet
Glutens
Therapeutics
Northern Asia
Northern Africa
Immune Tolerance
South America
Hordeum
Immunosuppressive Agents
Triticum
Small Intestine
Epitopes
Early Diagnosis
Immunization
Mucous Membrane
Eating
Inflammation
Biopsy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Recent advances in the understanding of celiac disease : Therapeutic implications for the management of pediatric patients. / Kwon, John H.; Farrell, Richard J.

In: Pediatric Drugs, Vol. 8, No. 6, 19.12.2006, p. 375-388.

Research output: Contribution to journalReview article

@article{e221e9f9ad7a4ec29e31f2659a41bf85,
title = "Recent advances in the understanding of celiac disease: Therapeutic implications for the management of pediatric patients",
abstract = "Celiac disease (CD) is an autoimmune condition occurring in genetically susceptible individuals characterized by inflammatory injury to the mucosa of the small intestine after the ingestion of wheat glutens or related barley and rye products. Originally thought to be highly prevalent only in Northern European populations, growing evidence indicates a much higher prevalence in many other regions, including the US as well as South America, North Africa, and Asia. The growing awareness that pediatric patients may present with quite diverse and protean manifestations and the significant impact of CD on childhood development has prompted efforts to increase CD awareness for the early diagnosis and treatment of this disease. The current diagnostic criteria for CD requires characteristic histologic findings in small bowel biopsies and clinical remission when placed on a gluten-free diet. Serologic testing for CD can provide additional support for the diagnosis of CD or a means to assess efficacy and adherence to a gluten-free diet. The mainstay of treatment remains the institution of a gluten-free diet. However, patients with refractory CD may require treatment with immunosuppressant medications. With the increased identification of specific gluten epitopes and understanding of the pathogenesis of CD, future therapies may rely on genetically altering gluten proteins, immunization techniques, or therapies focused on either the development of specific immune tolerance or regulation of mucosal inflammation.",
author = "Kwon, {John H.} and Farrell, {Richard J.}",
year = "2006",
month = "12",
day = "19",
doi = "10.2165/00148581-200608060-00005",
language = "English (US)",
volume = "8",
pages = "375--388",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Recent advances in the understanding of celiac disease

T2 - Therapeutic implications for the management of pediatric patients

AU - Kwon, John H.

AU - Farrell, Richard J.

PY - 2006/12/19

Y1 - 2006/12/19

N2 - Celiac disease (CD) is an autoimmune condition occurring in genetically susceptible individuals characterized by inflammatory injury to the mucosa of the small intestine after the ingestion of wheat glutens or related barley and rye products. Originally thought to be highly prevalent only in Northern European populations, growing evidence indicates a much higher prevalence in many other regions, including the US as well as South America, North Africa, and Asia. The growing awareness that pediatric patients may present with quite diverse and protean manifestations and the significant impact of CD on childhood development has prompted efforts to increase CD awareness for the early diagnosis and treatment of this disease. The current diagnostic criteria for CD requires characteristic histologic findings in small bowel biopsies and clinical remission when placed on a gluten-free diet. Serologic testing for CD can provide additional support for the diagnosis of CD or a means to assess efficacy and adherence to a gluten-free diet. The mainstay of treatment remains the institution of a gluten-free diet. However, patients with refractory CD may require treatment with immunosuppressant medications. With the increased identification of specific gluten epitopes and understanding of the pathogenesis of CD, future therapies may rely on genetically altering gluten proteins, immunization techniques, or therapies focused on either the development of specific immune tolerance or regulation of mucosal inflammation.

AB - Celiac disease (CD) is an autoimmune condition occurring in genetically susceptible individuals characterized by inflammatory injury to the mucosa of the small intestine after the ingestion of wheat glutens or related barley and rye products. Originally thought to be highly prevalent only in Northern European populations, growing evidence indicates a much higher prevalence in many other regions, including the US as well as South America, North Africa, and Asia. The growing awareness that pediatric patients may present with quite diverse and protean manifestations and the significant impact of CD on childhood development has prompted efforts to increase CD awareness for the early diagnosis and treatment of this disease. The current diagnostic criteria for CD requires characteristic histologic findings in small bowel biopsies and clinical remission when placed on a gluten-free diet. Serologic testing for CD can provide additional support for the diagnosis of CD or a means to assess efficacy and adherence to a gluten-free diet. The mainstay of treatment remains the institution of a gluten-free diet. However, patients with refractory CD may require treatment with immunosuppressant medications. With the increased identification of specific gluten epitopes and understanding of the pathogenesis of CD, future therapies may rely on genetically altering gluten proteins, immunization techniques, or therapies focused on either the development of specific immune tolerance or regulation of mucosal inflammation.

UR - http://www.scopus.com/inward/record.url?scp=33845476847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845476847&partnerID=8YFLogxK

U2 - 10.2165/00148581-200608060-00005

DO - 10.2165/00148581-200608060-00005

M3 - Review article

VL - 8

SP - 375

EP - 388

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

IS - 6

ER -